© 2020 MJH Life Sciences and Urology Times. All rights reserved.
Prostate Cancer
AUA 2020: Experts explain new guideline for advanced prostate cancer
June 29, 2020
William Lowrance, MD, and Michael S. Cookson, MD, highlight the core components of the new AUA Guideline for Advanced Prostate Cancer.
Consensus guideline for advanced prostate cancer released by AUA, ASTRO, and SUO
June 25, 2020
The American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology have released a joint guideline for advanced prostate cancer to address the growing treatment options and complexity of the paradigm.
Nerve sparing during robot-assisted radical prostatectomy linked to higher risk of ipsilateral positive surgical margins
June 24, 2020
A real-world analysis found that nerve sparing robot-assisted radical prostatectomy increased the risk of ipsilateral positive surgical margins.
Novel PSMA-targeted radioligand therapy shows promise in mCRPC
June 24, 2020
177Lu-PSMA-617, an investigational radioligand therapy, showed stronger clinical activity than cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel.
FDA grants relugolix priority review for advanced prostate cancer
June 22, 2020
The FDA has granted a priority review to relugolix for the treatment of patients with advanced prostate cancer
Ipatasertib plus abiraterone and prednisone delays progression in mCRPC with PTEN loss
June 19, 2020
Phase 3 data showed that the addition of the AKT inhibitor ipatasertib to standard therapy boosted radiographic progression-free survival in patients with advanced castration-resistant prostate cancer whose tumors had PTEN loss.
Circulating tumor cells are strong early signal of prostate cancer recurrence
June 18, 2020
Following radical prostatectomy, circulating tumor cells may indicate an increased risk of recurrence earlier than a PSA rise.
FDA approves pembrolizumab across TMB-high solid tumors
June 17, 2020
Pembrolizumab has been granted a second tumor-agnostic FDA indication, this one for patients with solid tumors with a high tumor mutational burden.
MRI-guided laser focal therapy achieves impressive precision and safety in prostate cancer
June 16, 2020
MRI-guided laser focal therapy showed a better safety profile than standard treatments for patients with localized prostate cancer.
ADT-free option shows potential in advanced castration-sensitive prostate cancer
June 15, 2020
The regimen of apalutamide, abiraterone acetate, and prednisone showed viability as an ADT-free alternative in patients with advanced prostate cancer with noncastrate testosterone levels.